Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Food Recall Warning (Allergen) - Apetito HFS brand and Heart to Home Meals brand meatball products recalled due to undeclared egg, milk, and wheat


Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/apetito-hfs-brand-and-heart-home-meals-brand-meatball-products-recalled-due-undeclared

OTTAWA, ON, Feb. 3, 2023 /CNW/ -

Summary

Affected products

Brand

Product

Size

UPC

Codes

Undeclared Allergen

Apetito HFS

Meatballs in Gravy

329 g

None

23 DE 22

Egg, Wheat

Apetito HFS

Meatballs and Peppers

337 g

None

23 DE 12

23 DE 20

Egg, Wheat

Heart to Home Meals

Honey Garlic Meatballs

318 g

None

23 NO 29

24 JA 09

Egg, Milk

Heart to Home Meals

Spaghetti and Meatballs

356 g

None

23 DE 19

Egg, Milk

Heart to Home Meals

Sweet and Sour Meatballs

305 g

None

23 NO 29

Egg, Milk

Heart to Home Meals

Meatballs in Mushroom Sauce

364 g

None

23 DE 01

24 JA 10

Egg, Milk, Wheat

Issue

The affected products are being recalled from the marketplace because they contain egg, milk, and wheat which are not declared on the label.

The recalled products have been sold in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, and Nova Scotia.

What you should do

Learn more:

Background

This recall was triggered by the company.

There have been no reported reactions associated with the consumption of these products.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products.

The CFIA is verifying that industry is removing recalled products from the marketplace.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: